Approval · Notice of Compliance 24936 · 2021

FOSRENOL: Notice of Compliance 24936

Issued January 6, 2021

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number: 24936
Date: January 6, 2021
Company: Takeda Canada IncorporatedToronto, Ontario, Canada
Product type: Prescription Pharmaceutical
Submission: New Drug Submission (NDS)
Submission class: Labelling Only
Reason: Manufacturer change and update to product mongraph format

Products in this notice

Brand	DIN	Status today
FOSRENOL	02287145	Cancelled Post Market
FOSRENOL	02287153	Cancelled Post Market
FOSRENOL	02287161	Cancelled Post Market
FOSRENOL	02287188	Cancelled Post Market

Medicinal ingredients

LANTHANUM CARBONATE HYDRATE 250 MG per TAB
LANTHANUM CARBONATE HYDRATE 500 MG per TAB
LANTHANUM CARBONATE HYDRATE 750 MG per TAB
LANTHANUM CARBONATE HYDRATE 1,000 MG per TAB